Valion Bio, Inc. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
On October 26, 2026, Valion Bio closed two financing tranches: (1) 3i, LP purchased 50 Series B Preferred Shares for $50,000 with warrants to purchase 1,539 common shares at $1.0092/share; (2) multiple purchasers (including 3i, LP) purchased 4,717.73 Series C Preferred Shares for aggregate $4,717,717.61 ($3.2M via cash true-up credits, $1.5M cash) with warrants to purchase 2,524,343 common shares at $1.0092/share. 3i, LP has already purchased $13.637M of the $75M total Series C commitment and holds a $16.25M Senior Secured Convertible Note. Company must list on Nasdaq Capital Market and file registration statements within 30-60 days.
Why this rating
Raises $4.7M cash (118% of company's $4.0M market cap), critical for runway; Nasdaq listing requirement signals growth ambitions; 3i, LP's large prior commitments ($30M+) demonstrate sustained institutional confidence.
Price action (we called it positive)
before filing · preread $0.74 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.